Related Experiment Videos
Epitope specificity of the protective immune response induced by individual bovine herpesvirus-1 glycoproteins
S van Drunen Littel-van den Hurk1, G A Gifford, L A Babiuk
1Veterinary Infectious Disease Organization, University of Saskatchewan, Saskatoon, Canada.
Affinity-purified bovine herpesvirus-1 (BHV-1) glycoproteins gI, gIII and gIV, as well as a virus-free BHV-1-infected cell lysate were injected intramuscularly into seronegative calves. All immunized animals developed specific serum-neutralizing antibodies and they were fully protected from disease, using a BHV-1/Pasteurella haemolytica challenge model. After challenge, viral replication in the nasal passages was significantly reduced in animals vaccinated with gIV (10,000-fold) or BHV-1-infected cell lysate (450,000-fold) but just slightly reduced in animals immunized with gI (500-fold) or gIII (25-fold). All of the known epitopes of the glycoproteins were retained during the affinity-purification or preparation of the cell lysate. The high level of protection induced by gIV and the virus-infected cell lysate in particular indicates the potential of glycoprotein gIV as a subunit vaccine, ideally in combination with component(s) from the cell lysate, which may mediate cellular immune responses.
Affinity-purified bovine herpesvirus-1 (BHV-1) glycoproteins gI, gIII and gIV, as well as a virus-free BHV-1-infected cell lysate were injected intramuscularly into seronegative calves. All immunized animals developed specific serum-neutralizing antibodies and they were fully protected from disease, using a BHV-1/Pasteurella haemolytica challenge model. After challenge, viral replication in the nasal passages was significantly reduced in animals vaccinated with gIV (10,000-fold) or BHV-1-infected cell lysate (450,000-fold) but just slightly reduced in animals immunized with gI (500-fold) or gIII (25-fold). All of the known epitopes of the glycoproteins were retained during the affinity-purification or preparation of the cell lysate. The high level of protection induced by gIV and the virus-infected cell lysate in particular indicates the potential of glycoprotein gIV as a subunit vaccine, ideally in combination with component(s) from the cell lysate, which may mediate cellular immune responses.